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I) Introduction 
The 90-kDa heat shock protein 90, Hsp90, belongs to 
the family of molecular chaperone responsible for the 
conformational maturation or reparation of other 
proteins, referred to as "clients", into biologically active 
structures (Pearl and Prodromou, 2006). Hsp90 exerts 
its essential ATP dependant chaperone function to 
more than three hundred client proteins involved in cell 
growth, differentiation and survival (Workman, 2004; 
Chiosis et al., 2004; Sreedhar et al., 2004b; Zhang and 
Burrows, 2004; Neckers, 2002). Many of them, more 
than forty, include overexpressed or mutant oncogenic 
proteins ErbB2/HER2 (Miller et al., 1994; An et al., 
1997), Braf (Grbovic et al., 2006), Akt/PKB (Sato et 
al., 2000), muted p53  
(Blagosklonny et al., 1996), transcription factors: 
hormone steroid receptors GR (Grad and Picard, 2007) 
ER and AR, angiogenic factors HIF-1α (Picard, 2006; 
Kuduk et al., 2000; Kuduk et al., 1999; Johnson and 
Toft, 1995), telomerase (Forsythe et al., 2001; Akalin et 
al., 2001) which are associated with the six hallmarks 
of cancer (Figure 1).  
Under non-stress conditions the quaternary structure of 
Hsp90 is now well established to be a dimeric complex, 
and its abundance is approximately 1% of the total 
protein contents. Each monomer consists in three 
domains: the N-terminal domain (NTD), a middle 
domain (MD) implicated in client protein binding, and 
a C-terminal dimerization domain (CTD) (Figure 2) 
(Harris et al., 2004; Shiau et al., 2006).  
 
Figure 1: Hsp90 protein partners and clients destabilized by Hsp90 inhibition (Jackson et al., 2004). 
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Figure 2: Structure of the full length yeast Hsp90, in complex with non hydrolysable ATP analogue (Hsp90 ATP) and structure of the full 
length E. coli Hsp90 without nucleotide (Hsp90 apo) (Shiau et al., 2006).  
 
In the human proteome, several isoforms of Hsp90 
have been isolated, Hsp90α (inducible form) and 
Hsp90β (constitutive form) localized in cytoplasm 
(Sreedhar et al., 2004a), while Grp94 (glucose-
regulated protein) and TRAP-1 (HSP75/tumor necrosis 
factor receptor associated protein 1) are localized in the 
endoplasmic reticulum and in mitochondria 
respectively (Csermely et al., 1998; Maloney and 
Workman, 2002). To acquire its full active molecular 
chaperone activity, Hsp90 operates with molecular co-
chaperones and partner proteins to form a series of 
multimeric protein complexes (Figure 3) including 
Hsp70, peptidyl-prolyl isomerases, immunophilins 
(FKBP51 and FKBP52) and the cyclophilin CYP40. 
Others co-chaperones such as p23, recently identified 
as a prostaglandine E2-Syntase, plays an important role 
in the activity of a number of transcription factors of 
the steroid/thyroid receptor family (Chan et al., 2008; 
Grad et al., 2006). 
It is now well established, that Hsp90 needs to bind 
ATP in a pocket located in the N-terminal domain to 
exert its function. Thus, the Hsp90 protein function 
may be inhibited by molecules competing with ATP 
binding (such as geladanamycin: GA, Figure 3), 
thereby freezing the chaperone cycle, which in turn 
decreases the affinity of Hsp90 for client proteins and 
leads to 26S proteasome-mediated oncogenic client 
protein degradation (Sepp-Lorenzino et al., 1995). N-
terminal domain Hsp90 inhibitors block cancer cell 
proliferation in vitro and cancer growth in vivo (Sharp 
and Workman, 2006). 
To date, the full crystal structure of Hsp90 in complex 
with a non hydrolysable ATP analogue (Ali et al., 
2006), and of the full length E.Coli Hsp90 without 
nucleotide (apo-Hsp90) (Shiau et al., 2006), have yet 
been reported (Figure 2). Furthermore, an interesting 
recent study investigated Hsp90 conformational 
changes in solution, shows a long range effects 
between Hsp90  
domains, as the binding of co-chaperones (or 
inhibitors) at NTD induce conformational changes in 
the MD and CTD (Phillips et al., 2007). The C-terminal 
domain has been implicated biochemically as the site of 
a possible second, cryptic ATP-binding site on Hsp90. 
Its contribution to the overall regulation of chaperone 
function is not clear, but the antibiotic novobiocin 
(Nvb) (c.f. structure in Figure 15) has been reported to 
bind this site and alter the conformation of the 
chaperone (Yun et al., 2004). 
Since pharmacological inhibition of Hsp90 by several 
families of small molecules leading to the degradation 
of oncogenic proteins, Hsp90 has become a target of 
interest against cancer and allowed the development of 
numerous small inhibitors (Biamonte et al., 2010). 
II) Hsp90 health and cancer (Powers and 
Workman, 2007) 
Hsp90 has probably been most widely acknowledged 
as a therapeutic target for the treatment of cancer 
(Mitsiades et al., 2007). Although there is no evidence 
of Hsp90 mutations in malignancy, there is increasing 
support for the view that this molecular chaperone 
plays an important role in the development, 
maintenance and progression of cancers. 
One of the principal debates concerning the inhibition 
of the highly abundant Hsp90 is the selectivity of 
inhibitors for the chaperone protein in malignant cells 
(Kamal et al., 2003). Some works suggest that Hsp90 
inhibitors could provide an exploitable therapeutic 
index (Banerji, 2005). Firstly, it has been reported that 
inhibitors were significantly more sensitive to Hsp90 in 
cancer cells (Neckers and Neckers, 2005; Powers and 
Workman, 2006; Chiosis, 2006; Whitesell et al., 1994; 
Neckers, 2006). In support to this surprising 
observation, Kamal et al. showed that the activity state 
of the Hsp90 chaperone machine was different in tumor 
cells. 
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Figure 3: Hsp90 cycle: GA: geldanamycin analogue; 40=Hsp40; 70=Hsp70; IP: immunophillin; HIP: Hsp70-interacting protein; 
HOP=Hsp70/Hsp90 organizing protein (Biamonte et al., 2010). 
 
Indeed, the Hsp90 is entirely bound in an active 
complex with co-chaperones, whereas most Hsp90 in 
normal tissues resides in a free, uncomplexed state 
(Workman, 2004; Kamal et al., 2003). Furthermore, 
Hsp90 is constitutively expressed at higher levels (2-10 
fold) in tumor cells compared with their normal 
counterparts. This higher Hsp90 activity is probably 
due to the overexpression/amplification of mutated 
Hsp90 clients, and this is in correlation with the higher 
level of cochaperones of Hsp90 observed in cancerous 
cells. 
Finally, the selective sensitivity of transformed cells for 
Hsp90 inhibitors may be partly due to the selective 
accumulation of these drugs in cancer cells since the in 
vivo observation of Hsp90 inhibitors in murine model 
system showed higher concentration in tumor tissue 
(Chiosis and Neckers, 2006). 
Consequently, the Hsp90 has emerged as an exciting 
target for the development of cancer 
chemotherapeutics. However, despite the numerous 
molecules which have prompted a phase I clinical trial, 
it remains to be verified if Hsp90 inhibitors will 
provide adequate treatment in clinic. 
III) Hsp90 inhibitors (Messaoudi, 2008) 
The Hsp90 protein function may be inhibited with 
molecules that bind the ATP pocket, or its chaperone 
activity may be disturbed by small molecules binders 
interfering with domains in the C-terminus or median 
region. Although Hsp90 function provides an attractive 
target for the treatment of cancer, the feasibility and 
efficacy of the inhibitors approach has just begun to be 
explored in clinic. 
Direct inhibitors of Hsp90 have been divided into two 
groups: 
A) N-terminal domain binders 
1) Ansamycin macrolactames 
1.a) Quinone derivatives 
Geldanamycin (Figure 4), was isolated from the broth 
of Streptomyces hygroscopicus in 1970s (De Boer et 
al., 1970). Further studies have shown that GA revert 
the phenotype of v-src oncogene transformed cells. 
However, this ability was not due to a direct action of 
the Src kinase activity, but to an inhibition of Hsp90. 
Subsequent immunoprecipitation and X-ray 
cristallographic studies have shown that GA competes 
with ATP and binds to the N-terminal domain site of 
Hsp90, leading the Hsp90 multichaperone complexes 
to the ubiquitin-mediated proteasome degradation (Roe 
et al., 1999; Stebbins et al., 1997). Since this 
observation, GA was used to identify additional Hsp90 
substrates and to understand the role of Hsp90 in 
promoting malignant transformation. Although GA 
provided very promising antitumor effects, it showed 
several pharmacologic limitations as poor solubility, 
limited in vivo stability and high hepatotoxicity in some 
of the human tumor models (Neckers, 2006; Supko et 
al., 1995). Thus, the 17-position of GA has been an 
attractive focal point for the synthesis of GA analogues. 
Structure-activity relationship (SAR) studies have 
shown that structurally and sterically diverse 17-
substituents  
can be introduced without destroying antitumor 
activity. Then, further derivatives of GA, with similar 
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biological behaviour but a better toxicity profile, were 
synthesized (Schulte and Neckers, 1998). Therefore, 
new C-17 substituted derivatives 17-AAG (17-allyl-17-
desmethoxygeldanamycin, also designed KOS953, 
CNF 1010, tanespimycin, Figure 4) and 17-DMAG 
(17-(2-dimethylaminoethylamino)-17-
desmethoxygeldanamycin, KOS1022, alvespimycin, 
Figure 4) (Snader et al., 2002; Solit et al., 2007) were 
brought to the fore by displaying a significant 
enhancement of the chemical/metabolic stability. 
17-AAG can be used in single agent or in combination 
with other cancer therapeutics (KOS953/bortezomib 
(Anderson, 2007; Richardson et al., 2007), 
KOS953/trastuzumab (Modi et al., 2007), 17-
AAG/Paclitaxel (Sain et al., 2006), 17-AAG/cisplatin 
(McCollum et al., 2008)). 
To enhance the pharmacokinetics and dynamics of 17-
AAG, Kosan Biosciences Incorporated has developed a 
DMSO-free formulation (KOS953) contained 
cremophor, which is actually in Phase I clinical testing. 
Although 17-AAG and its numerous formulations have 
shown some encouraging clinical responses, they 
present important drawbacks (e.g.; liver toxicity and 
cumbersome formulation) that may limit their clinical 
applications whereas 17-DMAG exhibits a better water 
solubility and oral bioavailability (Ronnen et al., 2006). 
However, although clinical trials in myeloid leukemia 
seemed to be promising, the 17-DMAG was 
discontinued in 2008 (ClinicalTrials.gov). 
1.b) Hydroquinone derivatives 
In a different approach, Infinity Pharmaceuticals has 
developed IPI504 (retaspimycin or 17-AAG 
hydroquinone, Figure 4) (Adams et al., 2005; Sydor et 
al., 2006), a new GA analogue, in which the quinone 
moiety was replaced by a dihydroquinone one. Indeed, 
the preclinical data suggested that the hepatotoxicity of 
17-AAG was attributable to the ansamycin 
benzoquinone moiety, prone to nucleophilic attack. 
Furthermore, it was recently reported that the 
hydroquinone form binds Hsp90 with more efficiency 
than the corresponding quinone form (Maroney et al., 
2006). In biological conditions, the hydroquinone form 
can interconvert with GA, depending on redox 
equilibrium existing in cell. It has been recently 
proposed, that NQ01 (NAD(P)H: quinone 
oxidoreductase) can produce the active hydroquinone 
from the quinone form of IPI504 (Chiosis, 2006). 
However, Infinity Pharmaceuticals showed that if the 
overexpression of NQ01 increased the level of 
hydroquinone and cell sensitivity to IPI504, it has no 
significant effect on its growth inhibitory activity. 
These results suggest that NQ01 is not a determinant of 
IPI504 activity in vivo (Douglas et al., 2009). 
1.c) Clinical trials 
In 2007, results of the phase I clinical trial of 
tanespimicyn (KOS953) with bortezomib in patients 
with relapsed refractory multiple myeloma were 
reported (Solit and Chiosis, 2008; Taldone et al., 2008). 
Dose escalations in the trial ranged from 100 to 340 
mg/m
2
 for tanespimycin, and from 0.7 to 1.3 mg/m
2
 for 
bortezomib. Results showed that two patients, on the 41 
enrolled, exhibited stable disease after two cycles, and 
18 of them demonstrated a response to combination 
(Richardson et al., 2007). Moreover, the tanespimicyn 
was co-administrated with trastuzumab on 25 patients 
treated with up to 450 mg/m
2
 of drug on a weekly 
schedule. This combination induced a regression of 21, 
22 and 25% in three patients, which had failed 
trastuzumab therapy, with HER2-amplified breast 
cancer (Modi et al., 2007). 
 
Figure 4: GA, 17-AAG, 17-DMAG and IPI504. 
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In 2008, Infinity Pharmaceuticals reported the results 
of a dose escalation Phase I/II clinical trial of 
retaspimycin hydrochloride in patients with metastatic 
and/or unresectable gastrointestinal stromal tumors 
(GIST) on a twice weekly schedule (400 mg/m
2
). 4 of 
the 18 patients enrolled, achieved a partial response and 
11/18 achieved stable disease. These results had 
initiated the phase III clinical trial of the study in 2008. 
However, Infinity Pharmaceuticals reported on April 
2009, the decision to end its phase III study (RING 
trial) of IPI504 hydrochloride in patients with 
refractory gastrointestinal stromal tumors (Infinity 
Press Release). The trial was based on 46 patients 
whose tumors persist despite treatment with Gleevec 
(imatinib) and Sutent (sunitinib). Resulting data 
showed a higher than anticipated mortality rate. In this 
heavily pretreated population, IPI504 was not tolerated 
(400 mg/m
2
 or placebo in 21 days cycles as a 30 min 
intravenous infusion twice weekly for 2 weeks 
followed by a 1 week rest) and the study was 
terminated early. 
Nevertheless, the IPI504 is still evaluating in phase II 
trials in patients with non-small cell lung cancer, and in 
combination with herceptin (trastuzumab) in patients 
with HER-2 positive metastatic breast cancer. 
In the same month, KOSAN, acquired by BMS in 2008, 
reported that the phase III clinical trial concerning the 
KOS953 or tanespimycin, in combination with 
Bortezomib in patients with multiple myeloma in first 
relapse has been suspended. This was probably a 
precaution as the metabolization of tanespimycin leads 
to IPI504. 
Conforma Therapeutics/Biogen idec developed a 
hydroquinone form of the 17-AAG (CNF1010), 
trapped as HCl salt, which was in clinical phase I 
against chronic lymphocytic leukemia. However, to 
date, this program is terminated. Moreover, the 
CNF1010 had started a phase III trial against GIST in 
2008. This study was also suspended due to the 
anticipated mortality rate of patients enrolled 
(ClinicalTrials.gov). Parallel efforts to improve the 
solubility and bioavailability of 17-AAG have led the 
NCI and Kosan to develop 17-DMAG (KOS1022) as a 
second generation alternative which has entered Phase I 
clinical testing (Santi et al., 2007). Promising results 
were obtained in patients with chemotherapy refractory 
acute myelogenous leukemia, as 3 of 17 patients had a 
complete response to therapy (Lancet et al., 2006). 
However, researches were given up in 2008, as the 17-
DMAG presents an unusable toxicity profile. 
1.d) Other analogues 
Diverse derivatives of 17-AAG bearing non-redox-
active phenol group designed by Kosan Biosciences 
were reported (Tian et al., 2007). Amongst them, 
KOSN1559 was claimed as the most potent Hsp90 
inhibitor (e.g.; SKBr3 Cell Line IC50=860 nM, Kd=16 
nM) (Figure 5). To date, no clinical trial had been 
reported with this compound. 
 
Figure 5: Structure of KOSN 1559.  
 
2) Purines 
2.a) Purines analogues  
Limitations in the clinical use of 17-AAG and 17-
DMAG have prompted the discovery of novel Hsp90 
ATPase inhibitors with improved "drug-like" structural 
characteristics and better pharmacological profiles. To 
this end, structure-based design and high-throughput 
screening approaches performed at the Memorial 
Sloane Kettering Institute, have been taken to identify 
new chemotypes that inhibit Hsp90 ATPase activity. A 
significant breakthrough in the preparation of synthetic 
Hsp90 inhibitor was the PU3 (Figure 6). On the basis 
of X-ray analysis and molecular modelling, Chiosis's 
group, showed that PU3 was designed to place the 
purine moiety into the same spatial orientation as 
adenine ring of ATP in the nucleotide pocket of Hsp90 
(Chiosis et al., 2001). PU3 presented molecular 
signature of Hsp90 inhibition, including the 
degradation of HER2, even if its affinity for Hsp90 is 
moderate. 
Chiosis's group and Conforma therapeutics/Biogen 
Idec optimized this class of compounds leading to new 
analogues bearing a thioether bridge to connect the 
purine nucleus to substituted phenyl rings. Among 
them, the PUH58 (Figure 7) (Llauger et al., 2005), an 
8-arylsulfanyl analogue of PU3, has been identified as 
the most potent and selective purine. Further efforts in 
optimization of this lead compound led to the 
development of PU24F-Cl, (Figure 7) which presents a 
higher affinity (30 times more than PU3) for the N-
terminus of the Hsp90, and low micromolar activity in 
a cell proliferation assay (Chiosis et al., 2002; 
Vilenchik et al., 2004). In an in vivo experiment in 
MCF-7 tumor bearing mice, PU24FCl led to 70% 
inhibition when administered at a dose of 200 mg/kg 
every second day for 30 days (Vilenchik et al., 2004). 
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Figure 6: Co-crystal structures of ADP (left, in green) and PU3 (right, in magenta) with Hsp90. 
 
Figure 7: Structures of PU24FCl and analogues. 
 
Additional investigations concerning the 
pharmacophore of this family were done. It was 
demonstrated that the presence of an amino group on 
the C2 position of the purine nucleus respects the 
global size of the molecule in regard to the parent one 
(PU3). In addition, it offers multiple possibilities for 
hydrogen bonding, and thus allowed the connection of 
the benzyl group on the N-9 rather than the C-8 of the 
purine. Thus, Conforma-Biogen idec have identifed the 
BIIB021 (originally named CNF 2024, Figure 7) 
(Kasibhatla et al., 2007) which displayed a binding 
affinity of 1.7 nM (4.6 nM for 17-AAG) and induces 
degradation of HER2 with an IC50 of 38 nM in MCF-7 
cells (Lundgren et al., 2009). BIIB021 compound was 
entered in clinical trials in 2005. 
2.b) Clinical trial  
Currently, BIIB021 is the only purine analogue 
evaluated in phase I/II clinical trials in combination 
with trastuzumab (herceptin) against breast cancer, 
with an aromatase inhibitor (exemestane) in metastatic 
HER2-advanced breast cancer, or alone in subjects with 
gastrointestinal stromal tumors. Results from the phase 
I trials showed that BIIB021 was well tolerated (800 
mg twice weekly) and induced a significant inhibition 
of the HER2 (Elfiky et al., 2008). 
3) Pyrazole and isoxazole derivatives  
3.a) Pyrazole analogues 
In 2004, CCT018159 (Figure 8), the first Hsp90 
inhibitor in the pyrazole series, was identified by 
Workman et al. from a library of 60000 compounds, 
using a high throughput screening (HTS), in the Cancer 
Research UK Centre for Cancer Therapeutics 
(Rowlands, 2004). This compound inhibits the N-
terminal ATPase activity of yeast and human Hsp90 
with an IC50 of 7.1 and 3.2 µM, respectively (Cheung et 
al., 2005; Sharp et al., 2007a). Further HTS studies 
undertaken by Genomics institute of the Novartis 
Research Foundation (GNF) and based on time-
resolved fluorescence resonance energy transfer (TR-
FRET) had allowed identifying two leads, G3129 and 
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G3130 (Figure 8), amongst the one million molecules 
screened (Kreusch et al., 2005). However, both 
compounds exhibited relatively poor binding affinity to 
N-terminal domain of the Hsp90 (Kd=680 and 280 nM 
respectively). In SkBr3 breast cancer cells, G3130 
caused the degradation of HER2 (IC50=30 µM) while 
G3129 was ineffective. 
In addition, the co-crystal structures of G3129 and 
G3130, bound to the N-terminus of human Hsp90α, 
were reported (Kreusch et al., 2005). From this study, it 
was showed that the resorcinol ring bound Hsp90 in a 
similar way than that of radicicol, a resorcylic lactone 
that inhibits Hsp90. 
 
Figure 8: Structure of analogues G3129 and G3130. 
 
Figure 9: Co-crystal structure of G3130 bound to the N-terminus of human Hsp90α. 
 
Figure 10: VER49009 and VER50589. 
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Furthermore, the 5-ethyl appendage projected into the 
aromatic pocket that accommodates the benzyl group 
of the purine analogues described before. The pyrazole 
provides hydrogen bound acceptor, and the imidazole 
(G3130) occupies the same pocket as the quinone of 
GA (Figure 9). 
Based on these data, medicinal chemistry efforts led to 
the identification of the more potent analogue of 
CCT018159, the VER49009 (IC50 ATPase 
activity=0.14 µM, Figure 10), where the amide group 
was a key in forming a new interaction with the residue 
Gly97 of the protein (Dymock et al., 2005). 
Synta Pharmaceuticals Corp. had reported another 
class of triazoles analogues as modulators of Hsp90 
(Figure 11) (Ying et al., 2009). It has been shown that 
STA-9090, an unspecified new resorcinol-containing 
triazole compound (Lin et al., 2008), inhibits the 
activity of Hsp90 protein from 10 to 100 µM and 
thereby leading to degradation of Hsp90 client proteins 
such as HER2 gene product (Ying et al., 2009). More 
recently, it had been shown that the STA-1474, a 
highly soluble phosphate prodrug of STA-9090, 
exhibits very interesting biologic activity against 
osteosarcoma cell lines (McCleese et al., 2009). 
 
Figure 11: Pyrazoles reported by Synta Pharmaceuticals.  
3.b) Isoxazole analogues 
Further optimization of potency, pharmakinetic and 
pharmacodynamic properties of VER49009, were 
undertaken by Vernalis Ltd. (in collaboration with 
Novartis) to offer a series of isoxazole resorcinol 
inhibitors. One of these was the VER50589 (Figure 10) 
which exhibited a higher affinity (Kd=5 nM) than 
VER49009 (Kd=78 nM) (Sharp et al., 2007b). Thus, 
the pyrazole to isoxazole switch does not affect the 
critical hydrogen bound of the pyrazole resorcinol unit 
that anchors this class of inhibitors to the Hsp90 NH2-
terminal ATP site (Brough et al., 2008). Moreover, 
VER50589 also showed improved cellular uptake over 
VER49009. 
Brough et al. from Vernalis, reported recently the 
identification of new diarylisoxazole compound 
VER52296 (Figure 12) (Brough et al., 2008; Eccles et 
al., 2008). The areas of interest for SAR studies were 
the 5' positon on the resorcinol ring, and the para 
substitution of the phenyl group on the isoxazole ring. 
It has been shown with the X-ray cristal structure, that 
the replacement of the chlorine, in regard to 
VER50589, by an isopropyl group, results in an 
additional hydrophobic interaction with Leu107 in the 
flexible lipophilic pocket of the N-terminal site of 
Hsp90. Additional hydrophobic interactions were also 
observed with Thr109 and Gly135 from the morpholine 
moiety present in VER52296/NVP-AUY922 (Figure 
12). This latter, subsequently developed by Novartis, 
was found to be very potent in the Hsp90 Fluorescence 
Polarization binding assay (IC50=21 nM) and displays 
an average GI50 of 2-40 nM in antiproliferation assays 
against different human tumor cell lines (Brough et al., 
2008). In addition, as evaluated by cassette dosing to 
mice bearing subcutaneous HCT116 human colon 
cancer, VER52296/NVP-AUY922 was retained in 
HCT116 xenograft tumors when administered i.p., at 
concentrations well above the GI50. Further in vivo 
characterization in a human colon cancer xenograft 
model, VER52296/NVP-AUY922, also inhibits tumor 
growth by ~50% when dosed at 50 mg/kg i.p. daily. 
Moreover VER52296/NVP-AUY922 induces the 
degradation of HER2 with an IC50 of 7 nM. In addition, 
VER52296/NVP-AUY922 was tested in several 
xenografts (colon, glioblastoma, breast, ovarian, 
prostate) and a therapeutic response was observed in 
each case (Cheung et al., 2005; Jensen et al., 2008; 
Eccles et al., 2008). 
 
Figure 12: Structure of VER52296/NVP-AUY922. 
3.c) Clinical trials 
The VER52296/NVP-AUY922 is the sole isoxazole 
analogue currently in phase I/II clinical trials as a 
single agent or in combination with bortezomib or 
dexamethasone, in patients with relapsed or refractory 
multiple myeloma. AUY922 is also used as a single 
agent, in advanced solid malignancies and efficacy in 











 locally advanced or metastatic breast 
cancer patients. In this latter phase I/II trial, 
VER52296/NVP-AUY922 was intravenously 
administrated once a week schedule. The maximum 
dose reported is 54 mg/m
2
. At 40 mg/m
2
, VER52296 
induces an up regulation (4-19 fold) of Hsp70 and a 
20% reduction in soluble HER2 was achieved by 74% 
of patients. 
Noteworthy, the STA9090 (Figure 11) is currently 
enrolling patients in several phase I/II clinical trials 
against solid tumor, myeloid leukemia, non-small cell 
lung cancer and gastrointestinal stromal tumor. 
4) Dihydroindazolone derivatives 
4.a) SNX2112 and SNX5422 
In 2007, Serenex Inc./Pfizer had started a phase I 
clinical trial program for the SNX5422 (Figure 13). 
Using a new screening platform, the compounds 
retained on the ATP-affinity column were analyzed by 
mass spectrometry leading to the identification of a 
poorly soluble analogue, SNX2112, which will become 
the glycine prodrug SNX5422. The SNX2112 showed 
higher activity to bind Hsp90 (Ki=1 nM) than that of 
17-DMAG and induced the degradation of HER2 with 
an IC50 of 20 nM. Based on the observation that breast 
cancer cell lines with HER2 amplification are more 
sensitive to 17-AAG, the SNX2112 was tested using a 
panel of breast, lung, and ovarian cancer cell lines. In 
all cell lines studied, SNX2112 inhibited cell 
proliferation with IC50 ranging from 10 to 50 nmol/L. 
In contrast to 17-AAG, the sensitivity of cancer cell 
lines to SNX2112 in vitro did not correlate with the 
level of HER2 expression (Chandarlapaty et al., 2008; 
Huang et al., 2006). This compound uniformly targets 
both the pro-proliferation pathways driven by HER2 
and ERK as well as the anti-apoptotic Akt pathway 
(Okawa et al., 2009). Indeed, it exhibits potent in vivo 
antitumor activity that extends significantly the effects 
observed with GA analogues. 
4.b) Clinical trial 
SNX-5422 is currently in a phase I clinical trial in 
treating patients with solid tumor or lymphoma that has 
not responded to treatment. SNX5422 is equally  
tested to treat solid tumor cancer and lymphomas, and, 
in subjects with refractory hematological and solid 
tumor malignancies. In 2008, results of a phase I dose-
escalation study of SNX5422 reported that this 
compound was well tolerated at 21 mg/m
2
. 
5) Other inhibitors  
Another class of ATP Hsp90 inhibitors bearing a 
resorcinol moiety is radicicol (Rd) (Figure 14), a 
natural resorcylic lactone, isolated from the fungus 
Monocillium nordinii and Monosporium bonorden. Rd, 
also known as monorden, has been described to reverse 
the Src-transformed morphology of fibroblast 
(Whitesell et al., 1994). This effect was first attributed 
to the inhibition of the oncogenic Src (v-Src), and later 
proved to act as an inhibitor of Hsp90 despite its 
difference in structure to GA. Moreover, Rd was found 
to compete with GA for binding to the NTD of the 
chaperone, suggesting that Rd shares the geldanamycin 
binding site. This compound is a potent and specific 
inhibitor of the ATPase activity of Hsp90 with 
nanomolar affinity (Kd=19 nM). This causes 
destabilization of Hsp90 client proteins (v-Src, Raf-1, 
ErbB2 and Ras), many of which are essential for tumor 
cell growth. Although, the in vitro antitumoral activity 
of Rd is very promising however, its in vivo activity is 
very weak probably because of its chemical instability 
in serum and its rapid conversion into inactive 
metabolites due to the electrophilic nature of the 
dienone moiety. 
Therefore, synthetic efforts have been directed to 
identify radicicol derivatives with improved in vivo 
activity (Proisy et al., 2006). To date, Kyowa Hakko 
described novel oxime-derivatives of Rd, including 
KF55823 and KF25706 (Soga et al., 2003) (Figure 14). 
Although these compounds exhibit potent antitumor 
activities in preclinical models and do not seem to 
cause hepatotoxicity, their clinical evaluations of these 
compounds has not been pursued. 
 
Figure 13: Structure of SNX5422 and SNX2112. 
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Figure 14: Resorcylic inhibitors. 
 
 
Figure 15: Structures of novobiocin, chlorobiocin and coumermycin A1. 
 
B) C-terminal domain binders 
In 1991, Csermely, Kahn and co-workers reported the 
presence of a C-terminal ATP binding site on Hsp90 
which becomes accessible when the N-terminal 
Bergerat pocket is occupied (Sõti et al., 2002). A 
decade later, it has been shown that Nvb interacts with 
an ATP-binding domain in the C-terminus of Hsp90 
(Marcu et al., 2000a). Biochemical studies on the CTD 
of Hsp90 have identified an allosteric regulation 
process with the N-terminus site, where the occupancy 
of one site blocks the interaction of the ligand with the 
other site (Garnier et al., 2002). The structure of the full 
length and middle and C-terminal construction of 
Hsp90 with different nucleotide states (apo, ATP) have 
shown that there is a hinge region between the middle 
and C-terminal region of Hsp90. The conformation of 
this region is dictated by the status of the nucleotide at 
the N-terminal site. This observation is in accordance 
with the allosteric regulation of ATP binding. It 
suggests that the putative secondary ATP site could be 
located at the immediate proximity of the hinge. 
IV) Coumarin inhibitors 
Coumarin group antibiotics, such as novobiocin (Nvb), 
coumermycin A1 (Kd=10 nM) and clorobiocin (Figure 
15), are potent inhibitors of the bacterial ATP binding 
gyrase B, a type II DNA topoisomerase (Gormley et al., 
1996). Their affinity for gyrase is considerably higher 
than that of modern fluoroquinolones. These antibiotics 
have been isolated from various Streptomyces species 
(Lanoot et al., 2002) and all possess a 3-amino-4-
hydroxycoumarin moiety as a key structural feature. 
Nvb is licensed as an antibiotic for clinical use 
(Albamycin; Pharmacia-Upjohn) and for the treatment 
of infections with multi-resistant gram-positive bacteria 
such as Staphylococcus aureus and S. epidermidis  
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(Raad et al., 1995; Raad et al., 1998; Rappa et al., 
2000). It had been demonstrated that the interaction of 
Nvb with Hsp90 induces alteration in the affinity of the 
chaperone for GA and Rd and causes in vitro and in 
vivo depletion of key regulatory Hsp90-dependant 
kinases including v-Src, Raf-1 and ErbB2 (e.g., ErbB2 
in SkBr3 breast cancer cells ~700 µM). In addition, 
Nvb was found to bind the C-terminal nucleotide 
binding region of Hsp90, albeit with a lower affinity 
than with gyrase B. Moreover, Nvb disrupts the 
interaction of both the cochaperones p23 and HSC70 
with the Hsp90 complex. 
In 2005, the first attempt to improve the inhibitory 
activity of Nvb against Hsp90 was reported (Yu et al., 
2005; Blagg et al., 2006). These authors have 
highlighted the crucial role of the noviose moiety at the 
7-position of the coumarin ring for the biological 
activity. Compound A4 lacking the 4-hydroxyl of the 
coumarin moiety and containing an N-acetyl side chain 
in lieu of the benzamide was the most active 
compound. This compound was identified as Hsp90 
inhibitor that induced degradation of Hsp90-dependent 
client proteins at 70-fold lower concentration than Nvb. 
Recently, in continuation of their structural 
modification studies, the same authors reported that 3'-
descarbamoyl-4-deshydroxynovobiocin DHN2 (Figure 
16) and compound KU135 (Shelton et al., 2009) proved 
to be a more effective and selective Hsp90 inhibitor 
(degradation of ErbB2 and p53 between 0.1 and 1.0 
µM) (Burlison et al., 2006). 
Our group reported a novel series of 3-aminocoumarin 
analogues (Le Bras et al., 2007a; Le Bras et al., 2007b) 
lacking the noviose moiety as a class of highly potent 
Hsp90 inhibitors. A representative example of this new 
class of inhibitors is 4TCNA (Figure 17) (Le Bras et 
al., 2007b).  
In these analogues, the introduction of a tosyl 
substituent on C-4 position of coumarin nucleus 
(4TCNA) contributed to a significant extent for 
maximal activity despite weaker water solubility. 
Moreover, this lead has a particular implication in 
apoptotic process. Thus, 4TCNA promotes apoptosis 
through activation of caspases 7 and 8 in ER-positive 
MCF-7 human breast cancer cells, whereas in Ishikawa 
endometrial adenocarcinoma cells, it induced apoptosis 
that was associated with caspase activation and 
cleavage of PARP. Furthermore, characterization of its 
mode of action revealed that 4TCNA induced-cleavage 
of the p23, recently identified as a prostaglandine E2-
Syntase, which plays an important role in activity of a 
number of transcription factors of steroids/thyroid 
receptors family. These results demonstrate that this 
new denoviose compound presents originality in regard 
to Nvb osidic derivatives already known. 
In another study based on a simplified 3-
aminocoumarin scaffold, we also demonstrated that 4-
tosyl-7-deshydroxycyclonovobiocic acid (4TDHCNA) 
(Figure 17) (Radanyi et al., 2008), exhibit increased 
inhibitory activity against the Hsp90 protein folding 
process (MCF7 IC50=50 µM). 
This result shows that removal of C7/C8 substituents is 
not detrimental for Hsp90 inhibitory activity and 
strongly enhances the capacity of 4DHTCNA to inhibit 
Hsp90. This compound was identified to be the most 
potent representative of the new family of simplified 
coumarins. Results from this study suggest that 
4TDHCNA and 4TCNA, which exerted similar 
biological profile may be considered interesting 
compounds for the development of more potent 
novobiocin analogues. 
More recently, results from our group allowed the 
identification of a new family of novobiocin analogues 
in which the coumarin unit has been replaced by a 2-
quinoleinone moiety (unpublished results). The 
quinolone-scaffold represents a platform for the 
creation of easily synthesizable soluble molecules. 
Compound 4-tosyl-3[(chroman-6-yl) carboxylamino]-
2-quinolon (4TCCQ, Figure 17) (IC50=5-8 µM) is 100-
fold more potent than the parent natural compound 
(novobiocin) and 6-fold more active than the synthetic 
analogue 4TCNA. Additionally, 4TCCQ induces the 
degradation of ERα and strongly induces the cell death 
in MCF-7 breast cancer cell line.  
Overall, these data provides compelling evidence for 
the continued development of novobiocin-based C-
terminal domain Hsp90 inhibitors as promising 
alternative to N-terminal domain inhibitors. 
 
Figure 16: Structures of A4, DHN2 and KU135. 
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Figure 17: Structures of 4TCNA, 4TDHCNA and 4TTCQ. 
 
 
Figure 18: Tau-Hsp90 in AD. 
 
V) HSP 90 in Alzheimer's disease 
Hsp90, a molecular chaperone, has come into its own 
as a tantalizing target for cancer therapies. However, its 
important functions of stabilization, rematuration, 
disaggregation of many client proteins could be 
exploitable in others diseases.  
Indeed, neurodegenerative diseases are characterized 
by the accumulation of misfolded proteins that results 
in plaque formation. These proteins rely upon HSP's for 
their refolding and viability. Recently, it was suggested 
that Hsp90 may play a crucial role in maintaining 
pathogenic changes that lead to neurodegenerative 
diseases (Luo et al., 2008). Furthermore, the inhibition 
of Hsp90 by 17-AAG derivatives and geldanamycin, 
induces the HSP induction via HSF-1 activation, 
resulting in neuroprotective activities. In the 
Alzheimer's disease, the most common tauopathy, in 
addition to β-amyloid deposition, there is an 
accumulation of abnormal species of 
hyperphosphorylated protein tau which leads to the 
formation of toxic neurofibrillary tangles (Luo et al., 
2007; Dickey et al., 2007). This hyperphosphorylation 
is caused by abnormal kinases (CdK4, GSK-3β) 
activities resulting in dissociation of transformed tau 
from microtubules, aggregation and formation of 
neurofibrillary tangles which can block the synaptic 
transmission (Figure 18). 
Thus, the decrease of hyperphosphorylated tau levels 
through refolding or degradation may provide a 
possible therapeutic strategy against AD. In this 
purpose, Dickey and Luo have presented evidence that 
the stability of p35, (neuronal activator of CdK4) and 
P301L mutant (most common mutation in Alzheimer 
disease) are maintaining by Hsp90. 
Dou et al. 2007 reported that Hsp90 associates with 
GSK-3β, regulating its stability and function, 
preventing its degradation by the proteasome and so 
allowing the increase of tau hyperphosphorylation. 
Thus, the use of Hsp90 inhibitors leads to a 
destabilization of GSK-3β and to a decrease of 
hyperphosphorylated tau protein. 
Dickey et al. 2007 demonstrated that CHIP (a tau 
ubiquitin ligase) is intimately linked to tau degradation 
following Hsp90 inhibition and that this process is 
specific for promoting degradation of only aberrant 
phosphorylated tau due to the fact that the Hsp90 
complex, in AD brain, presents higher affinity for 
inhibitors than in unaffected brain tissue. 
Recently, compound A4 (Figure 16) was found to 
exhibit significant protection against the Aβ-induced 
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toxicity at low concentrations (Lu, 2009). These results 
suggest that novobiocin analogues may represent an 
effective class of novel compounds for treatment of 
AD. 
VI) Conclusion 
Since the first discovery of natural analogues, GA and 
RD, the search for inhibitors of Hsp90 has generated 
considerable interest as evidenced by the number of 
compounds in clinical evaluations (Table 1).  
However, if the first clinical results were very  
encouraging, it seems that currently the development of 
Hsp90 inhibitors experiencing some difficulties, 
especially due to their toxicity. Stopping clinical trials 
of IPI504, which represented the most advanced HSP90 
inhibitors, is the unfortunate illustration of that. Thus, 
many efforts are still needed in the understanding of the 
administration of these agents but also in the synthesis 
of new molecules. Moreover, the involvement of 
Hsp90 in other non-oncological diseases such as 
Alzheimer's disease shows the importance of acquiring 
new and more potent inhibitors with suitable 
pharmacological and pharmacokinetic profiles. 
 
Table 1: Current clinical trials.  
 
Condition: R: recruiting, ANR: active, not recruiting, C: completed, NYR: not yet recruiting, S: suspended, T: terminated.  
Therapy: ADL: Advanced Dedifferentiated Liposarcoma, AGC: Advanced Gastric Cancer, AM: Advanced Malignancies, AML: Acute 
Myeloid Leukemia, AST: Advanced Solid Tumors, BC: Breast Cancer, CLL: B-Cell Chronic Lymphotic Leukemia, CLL: Chronic 
Lymphocytic Leukemia, CML: Chronic Myelogenous Leukemia, ALL: Acute Lymphoid Leukemia, MM: Multiple Myeloma, MetM: 
Metastatic Myeloma, NSCLC: Non Small Cell Lung Cancer, PC: Prostate Cancer, GIST: Gastrointestinal Stroma Tumor, RRMM: 
Relapsed or Refractory Multiple Myeloma, ST: Solid Tumors, UST: Unresectable Solid Tumors. 
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